<DOC>
	<DOCNO>NCT02242045</DOCNO>
	<brief_summary>This study evaluate 28-day safety , tolerability , pharmacokinetics ( PK ) idelalisib without ofatumumab Japanese participant relapse refractory indolent non-Hodgkin lymphoma ( iNHL ) chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Idelalisib Japanese Adults With Relapsed Refractory Indolent B-Cell Non-Hodgkin Lymphomas Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Subjects mature Bcell malignancies indolent nonHodgkin lymphoma include follicular lymphoma , small lymphocytic lymphoma , lymphoplastic lymphoma , marginal zone lymphoma , chronic lymphocytic leukemia World Health Organization classification Must born Japan must live outside Japan &gt; 1 year 5 year prior Day 1 . Must able trace maternal paternal ancestry parent grandparents Japanese . Must previously treat least 1 regimen iNHL CLL currently require treatment . Discontinuation therapy ( include radiotherapy , chemotherapy , immunotherapy , investigational therapy ) treatment iNHL CLL ≥ 4 week prior Day 1 Eastern Cooperative Oncology Group performance status 0 1 Required baseline laboratory data ( within 4 week prior Day 1 ) A negative serum pregnancy test female subject childbearing potential Males female childbearing potential engage heterosexual intercourse must agree use protocolspecified method ( ) contraception . In judgment investigator , participation protocol offer acceptable benefittorisk ratio consider current disease status , medical condition , potential benefit risk alternative treatment individual 's disease . Key Known histological transformation aggressive histology Known presence myelodysplastic syndrome History iNHL CLL central nervous system involvement Life expectancy &lt; 120 day per investigator assessment History nonlymphoid malignancy follow exception : malignancy remission without treatment ≥ 5 year prior Day 1 , carcinoma situ cervix , adequately treat basal squamous cell skin cancer localize nonmelanoma skin cancer , surgically treat lowgrade prostate cancer , ductal carcinoma situ breast treat lumpectomy alone Ongoing druginduced liver injury , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , extrahepatic obstruction cause cholelithiasis , cirrhosis liver , portal hypertension History diagnosis pneumonitis interstitial lung disease . Ongoing inflammatory bowel disease Pregnancy breastfeed History prior allogeneic hematopoietic stem cell solid organ transplantation Concurrent participation another therapeutic clinical trial Prior ongoing clinically significant illness , medical condition , surgical history , physical finding , electrocardiogram finding , laboratory abnormality , investigator 's opinion , could adversely affect safety individual impair assessment study result . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>